IT IS WELL KNOWN that the decrease in circulating estradiol
|
|
- Rodney Patterson
- 6 years ago
- Views:
Transcription
1 X/00/$03.00/0 Vol. 85, No. 3 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Close Correlation between Estrogen Treatment and Renal Phosphate Reabsorption Capacity HIROKAZU UEMURA, MINORU IRAHARA, NAOTO YONEDA, TOSHIYUKI YASUI, KAORI GENJIDA, KEN-ICHI MIYAMOTO, TOSHIHIRO AONO, AND EIJI TAKEDA Departments of Obstetrics and Gynecology (H.U., M.I., N.Y., T.Y., T.A.) and Clinical Nutrition (K.G., K.-i.M., E.T.), The University of Tokushima, School of Medicine, Tokushima, Japan ABSTRACT To determine the influence of estrogen on the activity of renal proximal tubular reabsorption of inorganic phosphate (Pi) in women, we examined the changes of the renal threshold phosphate concentration (also denoted as TmP/GFR), as well as the changes in the concentrations of mineral components in the circulation in two groups of women one receiving hormone replacement therapy (HRT) and one receiving gonadotropin-releasing hormone agonists (GnRH-a) therapy. We also examined the changes in the concentrations of serum PTH in the GnRH-a group. The patients in the HRT group were continuously treated with mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate per day. The patients in the GnRH-a group were treated with a monthly injection of 3.75 mg leuprolide acetate depot for 6 months. The values of TmP/GFR decreased in all of the patients who received HRT. The mean percentage Received September 2, Revision received November 10, Accepted November 30, Address correspondence and requests for reprints to: Hirokazu Uemura, M.D., Department of Obstetrics and Gynecology, The University of Tokushima, School of Medicine, Kuramoto-cho, Tokushima, Japan. uemura@clin.med. tokushima-u.ac.jp. change in TmP/GFR was 14.5% (range, 24.3% to 9.6%). In contrast, in all of the patients treated with GnRH-a, the values of TmP/ GFR increased after 6 months of treatment (the mean percentage change was 28.5%; range, %) and returned to the preadministration level at 12 weeks after stopping therapy. In these patients, both the values of TmP/GFR and the concentrations of serum Pi correlated significantly with circulating estradiol levels (r 0.767, P 0.01 and r 0.797, P 0.01, respectively), but the concentrations of serum corrected calcium did not correlate. Moreover, in the same patients, the levels of serum intact PTH decreased significantly (P 0.05) after 6 months of treatment, but at 12 weeks after stopping therapy the trends of these levels varied among individual patients. These results suggest that estrogen could act directly to suppress sodium-dependent Pi reabsorption in the renal proximal tubules. (J Clin Endocrinol Metab 85: , 2000) IT IS WELL KNOWN that the decrease in circulating estradiol (E 2 ) in women at menopause is a major trigger of the changes in bone metabolism and causes the loss of bone density (1, 2). Administration of estrogen to postmenopausal women produces many health benefits, such as reduction of climacteric symptoms and prevention of arteriosclerosis (3, 4) and osteoporosis (5, 6). On the other hand, gonadotropinreleasing hormone agonists (GnRH-a) have been recognized to be effective against endometriosis by inducing the decrease in circulating E 2, leading to atrophy of both the endometrium and the endometriotic tissues. However, such long-term estrogen deficiency is likely to have a negative influence on bone density. Bone turnover is high at menopause. Estrogen reduces bone turnover and especially reduces bone resorption (7). By this action, the levels of circulating calcium (Ca) and inorganic phosphate (Pi) decrease in women who receive estrogen replacement (8 10). Renal proximal tubular reabsorption of Pi is a major determinant of the circulating level of Pi and contributes to the maintenance of Pi homeostasis. Pi reabsorption at the apical membrane is carried out by sodium-dependent Pi (Na/Pi) cotransporters, which are classified into types I and II by molecular characterization (11). Several hormonal and nonhormonal factors that control serum Pi homeostasis affect the rate of Pi reabsorption by changing the activities of type II Na/Pi cotransporter (12, 13). However, little is known about the effects of estrogen on renal phosphate reabsorption in women. To clarify this issue, we studied the effects of hormone replacement therapy (HRT) in climacteric women and of GnRH-a therapy in women with endometriosis on the renal phosphate threshold concentration (TmP/GFR) by modulating circulating E 2 levels. Experimental Subjects Patients and clinical treatment HRT treatment. Five Japanese women who had complained of various climacteric symptoms and/or had undergone surgical castration, aged yr (mean sd, ), with body mass indices ranging from kg/m 2 (mean sd, ) were studied after providing informed consent. They were treated with mg conjugated equine estrogens (CEE) (Premarin; Wyeth-Ayerst Laboratories, Inc., Radnor, PA) plus 2.5 mg medroxyprogesterone acetate (Provera; Upjohn Co., Kalamazoo, MI) per day. All patients had no history of estrogen-dependent cancer, hypercortisolism, hyperthyroidism, metabolic bone disease, or renal failure. All patients had both a negative mammogram and negative Papanicolaou smear within 6 months prior to the study. None of them had previously received estrogen replacement therapy or any drug treatment that might have affected Ca or Pi metabolism. GnRH-a treatment. Five Japanese women with endometriosis, aged yr and with body mass indices of
2 1216 UEMURA ET AL. JCE&M 2000 Vol 85 No 3 kg/m 2 (mean sd, ), were studied after providing informed consent. They were treated with a monthly injection of 3.75 mg leuprolide acetate (Leuprin; Takeda Pharmaceutical Co., Tokyo, Japan) depot for 6 months. All patients were in good health except for their endometriosis. None of them had received any other hormonal treatment for their endometriosis. Materials and Methods Mineral and hormone determination Fasted blood and urine samples were collected from the patients during HRT at the beginning and at the 6th month of treatment. They were also collected from the patients treated with GnRH-a at the beginning and end (i.e. at the 6th month) of treatment and at 12 weeks after stopping treatment. Serum was immediately separated after blood collection and promptly frozen at 40 C until the assay. Urine was also frozen and kept at 40 C until it was assayed. Serum E 2 was measured by a combination of high-performance liquid chromatography after extraction and RIA. The high-performance liquid chromatography was performed using a CAPCELL PAK NH2 column ( , 5 um; Shiseido Co., Tokyo, Japan). RIA was performed using a DSL Kit (Diagnostics Systems Laboratories, Inc., Webster, TX). The assay range was pg/ml. Intra- and interassay coefficients of variation were % and 15.5%, respectively. Serum intact PTH was measured by two-site immunoradiometric assay (Nichols, San Juan Capistrano, CA), with a normal range of pg/ml and assay sensitivity of 1 pmol/l. Pi concentration in serum and urine was analyzed by the method of Taussky and Shorr (14). Creatinine concentration in serum and urine was measured using a Creatinine-TEST Wako (Wako Pure Chemical Industries, Ltd., Osaka, Japan). Determination of TmP/GFR The activity of renal tubular reabsorption of Pi is best expressed as the renal threshold phosphate concentration (also denoted as TmP/GFR, or the ratio of maximum rate of renal tubular reabsorption of phosphate to GFR), which is independent of GFR and of net inflow of phosphate. TmP/GFR was calculated using a standard nomogram (15) and was expressed in millimoles per liter. Statistical analysis Data are expressed as the mean sd unless otherwise stated. Statistical significances were determined by t test and linear regression analysis. All P values of 0.05 or less were considered statistically significant. Analyses were carried out using a Stat Works program (Cricket Software, Inc., Philadelphia, PA). Results Changes in clinical values for serum and urine The changes in clinical chemical and hormonal values for serum and urine in patients during HRT are shown in Table 1. In all the patients, serum E 2 levels increased after 6 months of treatment, whereas the concentrations of both serum corrected Ca and serum Pi decreased. The changes in clinical chemical and hormonal values for serum and urine in patients who received GnRH-a therapy are shown in Table 2. In all patients treated with GnRH-a, the concentrations of serum E 2 decreased after 6 months of treatment and returned to the preadministration level at 12 weeks after stopping therapy, and the concentrations of both serum corrected Ca and serum Pi changed inversely to those of serum E 2. Changes in TmP/GFR The changes in the values of TmP/GFR in patients during HRT are shown in Fig. 1. In all of the patients, the values of TABLE 1. Parameters in serum and urine in patients who received HRT (n 5) Before TmP/GFR decreased after 6 months of treatment. The mean percentage changes in TmP/GFR was 14.5% (range, 24.3% to 9.6%). In contrast, in all of the patients treated with GnRH-a, the values of TmP/GFR increased after 6 months of treatment (the mean percentage change was 28.5%; range, %) and returned to the preadministration level at 12 weeks after stopping therapy (Fig. 2). Changes in levels of serum intact PTH The concentrations of serum intact PTH in the patients who received GnRH-a therapy decreased significantly (P 0.05) after 6 months of GnRH-a treatment, but at 12 weeks after stopping therapy the trends of these levels varied among individual patients (Fig. 3). Relationship between circulating E 2 and chemical values Because administration of CEE leads mainly to a rise in circulating estrone levels, we analyzed the correlations between circulating E 2 levels and other indices in the patients treated with GnRH-a. As shown in Fig. 4, the values of TmP/GFR correlated significantly with circulating E 2 levels (r 0.767, P 0.01). In these patients, the concentrations of serum Pi also correlated with circulating E 2 levels (r 0.797, P 0.01), but those of serum corrected Ca did not correlate with circulating E 2 levels. 6 M Serum Pi Ca Albumin Corrected Ca Creatinine Urine Pi Creatinine TmP/GFR (mg/100 ml) TABLE 2. Parameters in serum and urine in patients treated with GnRH-a (n 5) Before 6M (at the end of therapy) 12 weeks after stopping therapy Serum Pi Ca Albumin Corrected Ca Creatinine E 2 (pg/ml) intact PTH (pg/ml) Urine Pi Creatinine TmP/GFR (mg/100 ml)
3 ESTROGEN AND RENAL PHOSPHATE REABSORPTION 1217 FIG. 1. Changes in the values of TmP/GFR in the patients during HRT. In all patients, the values of TmP/GFR decreased after 6 months of treatment. The mean percentage change in TmP/GFR was 14.5% (range, 24.3% to 9.6%). FIG. 2. Changes in the values of TmP/GFR in patients receiving GnRH-a therapy. In all patients, the values of TmP/GFR increased after 6 months of treatment when therapy was completed (mean percentage change, 28.5%; range, %) and returned to the preadministration levels at 12 weeks after stopping therapy. Discussion Pi is essentially necessary to body functions because it is a constituent of the skeleton, membrane phospholipids, nucleic acids, and nucleotides. Moreover, it is necessary in many kinds of metabolic reactions and regulatory processes, including protein phosphorylation. Pi is widely recognized to be one of the most important constituent minerals of bone. The content of phosphorus in FIG. 3. Changes in the values of serum intact PTH in patients receiving GnRH-a therapy. The values of serum immunoreactive PTH decreased significantly (P 0.05) after 6 months of treatment when therapy was completed, but at 12 weeks after stopping therapy the trends of these levels varied among individual patients. the body increases from 4 5 g/kg at birth to g/kg in adulthood (16). And although levels of Pi are influenced by several factors, such as diet, intestinal absorption, bone metabolism, and renal reabsorption, Pi homeostasis in the body is mainly maintained by the mechanism of renal proximal tubular reabsorption. Previous studies in vivo and in vitro have reported that physiological regulation of proximal tubular Pi reabsorption is most likely related to the capacity of apical Na/Pi cotransport (13, 17, 19). In cases where bone resorption is accelerated, such as at menopause, phosphate enters the circulation along with Ca from bone. In contrast, administration of estrogen to women at menopause leads to a reduction of bone resorption (20), thereby suppressing the flux of Ca and Pi into the circulation and ultimately decreasing the circulating level of Pi. However, little is known about the effects of estrogen on renal reabsorption of Pi in women. In our studies, the values of TmP/GFR decreased with the increase of estrogen level in all women who received HRT, and it increased with the decrease of estrogen level in all women treated with GnRH-a. Administration of CEE to women leads mainly to a rise in the circulating estrone level, rather than in the E 2 level, and thus we analyzed the correlations between circulating E 2 levels and other indices in the patients treated with GnRH-a. We also studied the changes of serum intact PTH levels in these patients. The concentrations of circulating E 2 correlated to those of serum Pi but did not correlate to those of serum corrected Ca. These results suggest that estrogen regulates the renal proximal tubular Pi reabsorption directly or indirectly, but that estrogen does not regulate the renal Ca reabsorption. Previous studies have suggested that long-term estrogen administration leads to an increase in circulating immunoreactive PTH (21 23), due probably to a slight decrease in serum Ca resulting from inhibition of bone resorption. It is recognized that PTH has an inhibitory effect on the renal proximal tubular Na/Pi cotransporter (13, 19). Based on this
4 1218 UEMURA ET AL. JCE&M 2000 Vol 85 No 3 fact, we might offer another possible explanation that the effect of estrogen on the renal Na/Pi cotransporter might be mediated by the change of circulating PTH concentrations. However, although short-term administration of estrogen to postmenopausal women reduces circulating PTH, it also reduces the value of TmP/GFR (24). Therefore, the influence of estrogen on the change of TmP/GFR does not always occur through the change of circulating PTH. Moreover, Beers et al. (25) recently reported that in thyroparathyroidectomized and ovariectomized rats 17 -E 2 injection suppressed the capacity for Na/Pi cotransport across the renal brush border membrane. This report strongly suggests that estrogen has a direct inhibitory effect on the renal proximal tubular Na/Pi cotransporter in rats. In our studies, the values of TmP/GFR changed inversely to circulating E 2 levels, but the changes in TmP/GFR were not associated with the changes of serum intact PTH levels. Together with the results of Beers et al. (25), our present findings suggest that estrogen may regulate renal Pi reabsorption by acting directly on E 2 receptors in renal proximal tubular cells in women. However, a typical estrogen response element was not observed in the sequence of 5 -flanking region of a type II human Na/Pi transporter (NaPi-3) (26). Pi is an activator of bone turnover. It is well known that estrogen reduces bone turnover in postmenopausal women by its direct effect on osteoblasts, which have been shown to have estrogen receptors (27), and through several kinds of cytokines or growth factors (28, 29). Our results indicate the further possibility that estrogen may reduce bone turnover by reducing plasma Pi levels via a suppression in the capacity for Na/Pi cotransport across the renal brush border membrane. However, further investigation will be required to define the relationship between the bone turnover rate and circulating Pi level. In summary, we examined the relation between the changes of TmP/GFR and the changes in circulating E 2 levels in women treated with HRT or GnRH-a and found that the changes of TmP/GFR and circulating E 2 were inversely related, whereas those of TmP/GFR and serum intact PTH were not related. Our results suggest that estrogen could act directly to suppress the capacity for Na/Pi cotransport at the renal brush border membrane. To elucidate the detailed mechanisms of estrogens on renal Na/Pi cotransport, more fundamental studies will be needed. References FIG. 4. Correlations between the concentrations of circulating E 2 and the following indices in five patients treated with GnRH-a: TmP/GFR (A), concentration of serum Pi (B), and concentration of serum corrected Ca (C). The values of TmP/GFR correlated significantly with circulating E 2 levels (r 0.767, P 0.01). The concentrations of serum Pi also correlated with circulating E 2 levels (r 0.794, P 0.01), but those of serum corrected Ca did not correlate with circulating E 2 levels. 1. Lufkin EG, Wahner HW, O Fallon WM, et al Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 117: Raize LG, Shoukri KC Pathogenesis of osteoporosis. In: Mundy GR, Martin TJ, eds. Physiology and pharmacology of bone. Heidelberg: Springer- Verlag; Walsh BW Estrogen replacement and heart disease. Clin Obstet Gynecol. 35: Collins P, Rosano GM, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA Cardiovascular protection by oestrogen a calcium antagonist effect? Lancet. 341: Lindsay R, Aitkin JM, Anderson JB, Hart DM, MacDonald EB, Clarke AC Long-term prevention of postmenopausal osteoporosis by estrogen. Lancet. 1: Riis BJ, Thomsen K, Strom V, Christiansen C The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol. 156: Riggs BL, Jowsey J, Kelly PJ, Jones JD, Maher FT Effect of sex hormones on bone in primary osteoporosis. J Clin Invest. 48:
5 ESTROGEN AND RENAL PHOSPHATE REABSORPTION Stock JL, Coderre JA, Mallette LE Effects of a short course of estrogen on mineral metabolism in postmenopausal women. J Clin Endocrinol Metab. 61: Castelo-Branco C, Martinez-de-Osaba MJ, Pons F, Gonzalez-Merlo J The effect of hormone replacement therapy on postmenopausal bone loss. Eur J Obstet Gynecol Reprod Biol. 44: Stock JL, Coderre JA, Posillico JT Effects of estrogen on mineral metabolism in postmenopausal women as evaluated by multiple assays measuring parathyrin bioactivity. Clin Chem. 35: Murer H, Biber J A molecular view of proximal tubular inoganic phosphate (Pi) reabsorption and of its regulation. Pflugers Ach-Eur J Physiol. 433: Murer H, Biber J Renal tubular phosphate transport. In: Seldin GW, Giebisch G, eds. The kidney: physiology and pathophysiology, 2nd ed. New York: Raven; Bernet TJ, Knox FG Renal regulation of phosphate excretion. In: Seldin GW, Giebisch G, eds. The kidney: physiology and pathophysiology. New York: Raven; Taussky HH, Shorr E A microcolorimetric method for the determination of inorganic phophorus. J Biol Chem. 202: Walton RJ, Bijvoet OL Nomogram for derivation of renal threshold phosphate concentration. Lancet. 2: Forbes GB Growth, aging, nutrition and activity. In: Human body composition. New York: Springer Verlag; Murer H, Werner A, Reshkin S, Wuarin F, Biber J Cellular mechanisms in proximal tubular reabsorption of inorganic phosphate. Am J Physiol. 260:C885 C Deleted in proof. 19. Dennis VW Phosphate homeostasis. In: Windhager EE, ed. Handbook of physiology. New York: Oxford University Press; Riggs BL, Jowsey J, Kelly PJ, Jones JD, Maher FT Effect of sex hormones on bone in primary osteoporosis. J Clin Invest. 48: Riggs BL, Jowsey J, Goldsmith RS, Kelly PJ, Hoffman DL, Arnaud CD Short- and long-term effects of estrogen and synthetic anabolic hormone in postmenopausal osteoporosis. J Clin Invest. 51: Riggs BL Postmenopausal and senile osteoporosis: current concepts of etiology and treatment. Endocrinol Jpn. 26(Suppl): Gallagher JC, Riggs BL, DeLuca HF Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. J Clin Endocrinol Metab. 51: Stock JL, Coderre JA, Mallette LE Effects of a short course of estrogen on mineral metabolism in postmenopausal women. J Clin Endocrinol Metab. 61: Beers KW, Thompson MA, Chini EN, Dousa TP beta-estradiol inhibits Na -P(i) cotransport across renal brush border membranes from ovarectomized rats. Biochem Biophys Res Commun. 221: Taketani Y, Miyamoto K, Keiko T, et al Gene structure and functional analysis of the human Na /phosphate cotransporter. 324: Eriksen EF, Colvard DS, Berg NJ, et al Evidence of estrogen receptors in normal human osteoblast-like cells. Science. 241: Pacifici R, Rifas L, McCracken R, et al Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc Natl Acad Sci USA. 86: Pacifici R, Brown C, Puscheck E, et al Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA. 88:
Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women
Maturitas 50 (2005) 19 29 Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women Toshiyuki Yasui a,, Hirokazu Uemura a, Yuka Umino
More informationCIC EDIZIONI INTERNAZIONALI. Effects of the SERM raloxifene on calcium and phosphate metabolism in healthy middle-aged men.
Brigitte Uebelhart François Herrmann René Rizzoli Division of Bone Diseases [WHO Collaborating Center for Osteoporosis Prevention], Department of Rehabilitation and Geriatrics, Geneva University Hospitals
More informationDepartment of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament
Original Article Adequate Reduction Degree of Pituitary Gonadotropin Level in the Clinical Management of Short-Term Hormone Replacement Therapy of Women with Menopausal Symptoms Department of Obstetrics
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationRelationship between bone resorption and adrenal sex steroids and their derivatives in oophorectomized women
FERTILITY AND STERILITY VOL. 82, NO. 6, DECEMBER 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Relationship between bone
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationREVIEW POSSIBLE DELETION OF MEDROXYPROGESTERONE FROM THE 14 TH WHO MODEL LIST OF ESSENTIAL MEDICINES
REVIEW POSSIBLE DELETION OF MEDROXYPROGESTERONE FROM THE 14 TH WHO MODEL LIST OF ESSENTIAL MEDICINES Author: Lenita Wannmacher Application: To perform a quick review of medroxyprogesterone acetate tablet
More informationPseudohypoparathyroidism Showing Positive Phosphaturic and Negative Cyclic AMP Excretion Response to Parathyroid Hormone
Pseudohypoparathyroidism Showing Positive Phosphaturic and Negative Cyclic AMP Excretion Response to Parathyroid Hormone KIICHIRO HIGASHI, KENICHI HONDA*, MITSUO MORITA*, TERUHISA UMEDA*, TATSUYA SHIMADA,
More information25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?
Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force
More informationEndocrine Regulation of Calcium and Phosphate Metabolism
Endocrine Regulation of Calcium and Phosphate Metabolism Huiping Wang ( 王会平 ), PhD Department of Physiology Rm C516, Block C, Research Building, School of Medicine Tel: 88208252 Email: wanghuiping@zju.edu.cn
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationReproductive. Estrone sulfate Analyte Information
Reproductive Estrone sulfate Analyte Information - 1 - Estrone sulfate Introduction Estrone sulfate (E1-S) is a sulfate derivative of estrone, and is the most abundant form of circulating estrogens in
More informationThe hart and bone in concert
The hart and bone in concert Piotr Rozentryt III Department of Cardiology, Silesian Centre for Heart Disease, Silesian Medical University, Zabrze, Poland Disclosure Research grant, speaker`s fee, travel
More informationTreatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy*
Gynecology-endocrinology FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U S. A. Treatment of hirsutism with a gonadotropin-releasing hormone agonist
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationTHE RENAL HANDLING OF PHOSPHATE IN THYROID DISEASE
THE RENAL HANDLING OF PHOSPHATE IN THYROID DISEASE B. MALAMOS, P. SFIKAKIS and P. PANDOS Department of Clinical Therapeutics of the Athens Medical School, Alexandra Hospital, Athens, Greece (Received 18
More informationThomas Carpenter Yale University School of Medicine New Haven, Connecticut, USA
A Randomized, Open-label Phase 2 Study of, a Fully Human Anti-FGF23 Monoclonal Antibody, in 52 Children with X-linked Hypophosphatemia (XLH): 40-Week Results Thomas Carpenter Yale University School of
More informationW hile the headline-grabbing Women s
OBG MANAGEMENT BY ROBERT L. BARBIERI, MD New options in osteoporosis therapy: Combination and sequential treatment Perhaps the biggest medical question to emerge from the WHI study is how to best treat
More informationEuropean Journal of Endocrinology (1997) ISSN
European Journal of Endocrinology (1997) 137 167 171 ISSN 0804-4643 Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing
More informationAppendix: Reference Table of HT Brand Names
Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug
More informationDepot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome*t
FERTILITY AND STERILITY Vol. 62, No. 5, November 1994 Copyright 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Depot leuprolide acetate with estrogen and progestin add-back
More informationBone Health in Celiac Disease. Partha S. Sinha MD, PhD October 29 th, 2017
Bone Health in Celiac Disease Partha S. Sinha MD, PhD October 29 th, 2017 No Disclosures Objectives Recognize the mechanisms by which celiac disease can affect bone health Review what diagnostic tests
More informationDrugs Affecting Bone. Rosa McCarty PhD. Department of Pharmacology & Therapeutics
Drugs Affecting Bone Rosa McCarty PhD Department of Pharmacology & Therapeutics rmccarty@unimelb.edu.au Objectives At the end of this lecture you should have gained: An understanding of bone metabolism
More informationRENAL FUNCTION An Overview
RENAL FUNCTION An Overview UNIVERSITY OF PNG SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL MBBS II SEMINAR VJ. Temple 1 Kidneys
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationHypoparathyroid Patients *
Journal of Clinical Investigation Vol. 44, No. 6, 1965 Effects of Serum Calcium Level and Parathyroid Extracts on Phosphate and Calcium Excretion in Hypoparathyroid Patients * EUGENE EISENBERG t (From
More informationBEC FEED SOLUTIONS NEW ZEALAND Ltd
BEC FEED SOLUTIONS NEW ZEALAND Ltd Proudly sponsor Dr Alessandro Mereu Yara Feed Phosphates July 2017 NZARN Meeting www.becfeed.co.nz Phosphorus metabolism in cattle: principles and interactions with Ca
More informationINCREASED NEED FOR THYROXINE IN WOMEN WITH HYPOTHYROIDISM DURING ESTROGEN THERAPY
INCREASED NEED FOR THYROXINE IN WOMEN WITH HYPOTHYROIDISM DURING ESTROGEN THERAPY BAHA M. ARAFAH, M.D. ABSTRACT Background Women with hypothyroidism that is being treated with thyroxine often need higher
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationSouthern California Center for Sexual Health and Survivorship Medicine Inc, Newport Beach, CA 3
The WISDOM survey: Physicians Level of Comfort Prescribing Treatment for Vulvar and Vaginal Atrophy (VVA) Symptoms in Women with a Predisposition or History of Breast Cancer Lisa Larkin, MD 1 ; Michael
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationBone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases
Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral
More informationHRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
More informationDiagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome
Endocrine Journal 2007, 54 (2), 233 238 Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome TAKESHI IWASA, TOSHIYA MATSUZAKI, MASAHIRO MINAKUCHI, NAOKO
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationOsteoporosis: Risk Factors, Diagnostic Methods And Treatment Options
ISPUB.COM The Internet Journal of Academic Physician Assistants Volume 1 Number 1 Osteoporosis: Risk Factors, Diagnostic Methods And Treatment Options K Ihrke Citation K Ihrke.. The Internet Journal of
More informationThe Role of the Laboratory in Metabolic Bone Disease
The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology
More informationEffect of Growth Hormone on Tubular Transport of Phosphate
Journal of Clinical Investigation Vol. 43, No. 8, 1964 Effect of Growth Hormone on Tubular Transport of Phosphate in Normal and Parathyroidectomized Dogs * JACQUES CORVILAIN AND MAURICE ABRAMOW WITH THE
More informationEstrogens and progestogens
Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationPathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis. March 15, 2016 Bone ECHO Kate T Queen, MD
Pathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis March 15, 2016 Bone ECHO Kate T Queen, MD Review: normal bone formation Bone Modeling Remodeling Peak Bone Mass Maximum bone mass
More informationElecsys bone marker panel. Optimal patient management starts in the laboratory
bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic
More informationMedicine, Kyoto City, Japan
23 J. Physiol. (I959) I49, 23-33 SEASONAL VARIATIONS IN SERUM INORGANIC PHOSPHATE AND CALCIUM WITH SPECIAL REFERENCE TO PARATHYROID ACTIVITY BY M. IWANAMI, S. OSIBA, T. YAMADA AND H. YOSHIMURA From the
More information5. Summary of Data Reported and Evaluation
326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal
More informationRenal Na/P-cotransporters
Kidney International, Vol. 49 (1996), pp. 981 985 EPITHELIAL SODIUM-DEPENDENT Pi TRANSPORTERS Renal Na/P-cotransporters JURG BIBER, MARIA CUSTER, SIMONA MAGAGNIN, GILI HAYES, ANDREAS WERNER, MARIUS LOTSCHER,
More informationThe Parathyroid Glands
The Parathyroid Glands Bởi: OpenStaxCollege The parathyroid glands are tiny, round structures usually found embedded in the posterior surface of the thyroid gland ([link]). A thick connective tissue capsule
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014
HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research
More informationOMICS Journals are welcoming Submissions
OMICS Journals are welcoming Submissions OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationPrevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes*
FERTILITY AND STERILITY Vol. 59, No.5, May 1993 Copyright e 1993 The American Fertility Society Printed on acid-free paper in U.S.A. Prevention of endometrial hyperplasia by progesterone during long-term
More informationFemale Sexual Hormones Indications and Therapy
Female Sexual Hormones Indications and Therapy In puberty, a woman has about 400,000 ovules, at the age of 40-44 years about 17,000 only. On average, each grown-up woman (still having ovulation) loses
More informationResearch Article Study of Serum Calcium, Magnesium And Phosphorous Levels In Patients With Thyroid Disorders
Research Article Study of Serum Calcium, Magnesium And Phosphorous Levels In Patients With Thyroid Disorders Dr. Shweta R. Hebbar*, Dr. Nagarajappa. K., Dr. Sushma B. J, Dr. C. R. Mallikarjun Department
More informationREPRODUCTIVE ENDOCRINOLOGY
REPRODUCTIVE ENDOCRINOLOGY FERTILITY AND STERILITY VOL. 80, NO. 5, NOVEMBER 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A.
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationComparison of 2 Commercially Available Human Chorionic Gonadotropin Immunoassays Used in the Management of Gestational Trophoblastic Neoplasia
The Journal of Reproductive Medicine Comparison of 2 Commercially Available Human Chorionic Gonadotropin Immunoassays Used in the Management of Gestational Trophoblastic Neoplasia Hideo Matsui, M.D., Maki
More informationZurich Open Repository and Archive. The opossum kidney cell type IIa Na/P(i) cotransporter is a phosphoprotein
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2001 The opossum kidney cell type IIa Na/P(i) cotransporter is a phosphoprotein
More informationEuropean Journal of Endocrinology (2002) ISSN
European Journal of Endocrinology (2002) 146 635 642 ISSN 0804-4643 CLINICAL STUDY Diurnal rhythm of plasma 1,25-dihydroxyvitamin D and vitamin D-binding protein in postmenopausal women: relationship to
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationOBSTETRICS & GYNECOLOGY
AUGUST 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: BHRT for Menopause
More informationUniversity of Medicine and Pharmacy Craiova. Faculty of Medicine. PhD THESIS ABSTRACT
University of Medicine and Pharmacy Craiova Faculty of Medicine PhD THESIS ABSTRACT STUDY OF THE CHANGES IN BONE MASS AND BONE METABOLISM MARKERS IN THYROTOXIC OSTEOPOROSIS. THERAPEUTIC IMPLICATIONS. Scientific
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationEndocrine Steroids 2. Signal transduction 3. Prostaglandins
Endocrine - 2 1. Steroids 2. Signal transduction 3. Prostaglandins Estrogen Menopause (pause in the menes) ["change of life" at about 50] - lack of estrogen. (Some hysterectomy or ovarian cancer surgeries
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More information9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy
The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department
More informationEndocrine. Endocrine as it relates to the kidney. Sarah Elfering, MD University of Minnesota
Endocrine Sarah Elfering, MD University of Minnesota Endocrine as it relates to the kidney Parathyroid gland Vitamin D Endocrine causes of HTN Adrenal adenoma PTH Bone Kidney Intestine 1, 25 OH Vitamin
More informationGlycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy
Nephrol Dial Transplant (2008) 23: 315 320 doi: 10.1093/ndt/gfm639 Advance Access publication 23 October 2007 Original Article Glycaemic control and serum intact parathyroid hormone levels in diabetic
More informationHypothalamic Amenorrhea: To Treat or Not to Treat with Estrogen Replacement. Hypothalamic amenorrhea NASPAG ACRM 2015
Hypothalamic Amenorrhea: To Treat or Not to Treat with Estrogen Replacement Meredith Loveless, MD Gina Sucato, MD MPH NASPAG ACRM 2015 Hypothalamic amenorrhea Functional hypothalamic amenorrhea Absence
More informationPTH increases renal 25(OH)D 3-1 -hydroxylase (CYP1 ) mrna but not renal 1,25(OH) 2 D 3 production in adult rats
Am J Physiol Renal Physiol 284: F1032 F1036, 2003; 10.1152/ajprenal.00306.2002. PTH increases renal 25(OH)D 3-1 -hydroxylase (CYP1 ) mrna but not renal 1,25(OH) 2 D 3 production in adult rats H. J. Armbrecht,
More informationVitamin D: Is it a superhero??
Vitamin D: Is it a superhero?? Dr. Ashraf Abdel Basset Bakr Prof. of Pediatrics 1 2 History of vitamin D discovery Sources of vitamin D and its metabolism 13 Actions of vitamin D 4 Vitamin D deficiency
More informationUniversity of Zurich. What goes in must come out - the small intestine modulates renal phosphate excretion. Zurich Open Repository and Archive
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2007 What goes in must come out - the small intestine modulates renal phosphate
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationIndex. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition
A Acid base balance dietary protein detrimental effects of, 19 Acid base balance bicarbonate effects, 176 in bone human studies, 174 mechanisms, 173 174 in muscle aging, 174 175 alkali supplementation
More informationThe principal functions of the kidneys
Renal physiology The principal functions of the kidneys Formation and excretion of urine Excretion of waste products, drugs, and toxins Regulation of body water and mineral content of the body Maintenance
More informationBioidentical Hormones: Just the Facts
Bioidentical Hormones: Just the Facts Melissa McNeil, MD, MPH Professor of Medicine and Obstetrics, Gynecology and Reproductive Sciences Chief, Section of Women s Health University of Pittsburgh Disclosures!
More informationDiagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.
Diagnosis and Treatment of Osteoporosis Department of Endocrinology and Metabolism Ajou University School of Medicine Yoon-Sok CHUNG WCIM, COEX, Seoul, 27Oct2014 Case 1 71-year old woman Back pain Emergency
More informationEffects of dietary P i on the renal Na+-dependent P i transporter NaPi-2 in thyroparathyroidectomized rats
Biochem. J. (1998) 333, 175 181 (Printed in Great Britain) 175 Effects of dietary on the renal Na+-dependent transporter NaPi-2 in thyroparathyroidectomized rats Fumie TAKAHASHI*, Kyoko MORITA*, Kanako
More informationORILISSA (elagolix) oral tablet
ORILISSA (elagolix) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationLow & Ultra Low Dose HRT The Cardiovascular Impact
Low & Ultra Low Dose HRT The Cardiovascular Impact Wyeth Symposium, Turin 29 th Sept 2007 Nick Panay Consultant Gynaecologist Queen Charlotte s & Chelsea and Chelsea & Westminster Hospitals Honorary Senior
More informationAmani Alghamdi. Slide 1
Minerals in the body Amani Alghamdi Slide 1 The Minerals Small, naturally occurring, inorganic, chemical elements Serve as structural components Minerals classification The minerals present in the body
More informationmid ihsan (Physiology ) GFR is increased when A -Renal blood flow is increased B -Sym. Ganglion activity is reduced C-A and B **
(Physiology ) mid ihsan GFR is increased when A -Renal blood flow is increased B -Sym. Ganglion activity is reduced C-A and B ** Colloid pressure in the efferent arteriole is: A- More than that leaving
More informationProgesterone responsiveness is not downregulated in adenomyosis.
Progesterone responsiveness is not downregulated in adenomyosis. Takehiro Hiraoka Yasushi Hirota Tomoko Saito-Fujita Hirofumi Haraguchi Miyuki Harada Tetsuya Hirata Kaori Koga Osamu Hiraike Tomoyuki Fujii
More informationEVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES
Int. J. Chem. Sci.: 6(3), 2008, 1228-1235 EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES RAMPRASAD DEY, SUBHASH CHANDRA BISWAS, RANU ROY BISWAS a and ARUNIMA MUKHOPADHYAY
More informationEffect of hyperphosphatemia on gene expression of the Na-Pi cotransporter in rats
Effect of hyperphosphatemia on gene expression of the Na-Pi cotransporter in rats C. Zhang 1,2 *, L.-M. Shi 3 *, Y. Li 4 *, Q.-G Zhu 2 *, C.-L. Jin 2, H.-P. Wang 2, L. Zhou 2, X.-P. Hu 1, L. Zhang 1, H.
More informationCalcium metabolism and the Parathyroid Glands. Calcium, osteoclasts and osteoblasts-essential to understand the function of parathyroid glands
Calcium metabolism and the Parathyroid Glands Calcium, osteoclasts and osteoblasts-essential to understand the function of parathyroid glands Calcium is an essential element for contraction of voluntary/smooth
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationAcid-Base Balance 11/18/2011. Regulation of Potassium Balance. Regulation of Potassium Balance. Regulatory Site: Cortical Collecting Ducts.
Influence of Other Hormones on Sodium Balance Acid-Base Balance Estrogens: Enhance NaCl reabsorption by renal tubules May cause water retention during menstrual cycles Are responsible for edema during
More informationMonitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women
727 REVIEW Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women E Dogan, C Posaci... Biochemical markers of bone metabolism are divided into two groups:
More informationEffects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms
Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Photo (compulsory) Steven R Goldstein, MD 1 ; Ginger D Constantine, MD 2 ; David F Archer, MD 3 ; James H Pickar,
More informationEndometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY
Endometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY Natural Cycle FET Protocol for endometrial preparation N FET, including modified N FET HRT FET:
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More informationPARATHYROID, VITAMIN D AND BONE
PARATHYROID, VITAMIN D AND BONE G M Kellerman Pathology North Hunter Service 30/01/2015 BIOLOGY OF BONE Bone consists of protein, polysaccharide components and mineral matrix. The mineral is hydroxylapatite,
More informationMINERAL IMBALANCE, ENDOCRINES AND HAIR TISSUE MINERAL ANALYSIS
VOLUME 6 JUNE/JULY 1993 NUMBER 2 MINERAL IMBALANCE, ENDOCRINES AND HAIR TISSUE MINERAL ANALYSIS ----- David L. Watts, Ph.D., Director of Research ----------------------------------------------------------------------------------------
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationEstrogens & Antiestrogens
Estrogens & Antiestrogens Menstrual cycle... Changes and hormonal events Natural estrogens: Estadiol >> Estrone > Estriol Ineffective orally Synthesis: From cholesterol ; role of aromatase enzyme in converting
More informationReproductive. Estradiol Analyte Information
Reproductive Estradiol Analyte Information - 1 - Estradiol Introduction Estradiol (E2 or 17β-estradiol) is the major estrogen in humans. Although it is often called the "female" hormone, it is also present
More information